Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Dec 31;56(7):835–844. doi: 10.1002/jcph.668

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015, The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Strong correlations were observed between the treatment effects at 3 months and 6 months. (a) Scatter plot of the linear form of treatment effect, ΔACR50, at 6 months vs 3 months. (b) Scatter plot of log odds ratios of treated vs control at 6 months vs 3 months. The symbols represent different drug classes. The symbol size reflects the sample size for each treatment arm. The unity line represents equal efficacies at the 2 time points. Both plots suggest a similar mean effect after 3 months and 6 months for the trials tested in the database. With this data set the scaling factor was estimated to be 0.997 (95%CI: 0.903, 1.09). ACR50, American College of Rheumatology score 50; CI, confidence interval.